2o2m
From Proteopedia
| Line 7: | Line 7: | ||
|ACTIVITY= | |ACTIVITY= | ||
|GENE= BCL2L1, BCL2L, BCLX ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 Homo sapiens]) | |GENE= BCL2L1, BCL2L, BCLX ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 Homo sapiens]) | ||
| + | |DOMAIN= | ||
| + | |RELATEDENTRY= | ||
| + | |RESOURCES=<span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=2o2m FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=2o2m OCA], [http://www.ebi.ac.uk/pdbsum/2o2m PDBsum], [http://www.rcsb.org/pdb/explore.do?structureId=2o2m RCSB]</span> | ||
}} | }} | ||
| Line 44: | Line 47: | ||
[[Category: Wendt, M D.]] | [[Category: Wendt, M D.]] | ||
[[Category: Zhang, H.]] | [[Category: Zhang, H.]] | ||
| - | [[Category: LI0]] | ||
[[Category: apoptosis]] | [[Category: apoptosis]] | ||
[[Category: bcl]] | [[Category: bcl]] | ||
| Line 50: | Line 52: | ||
[[Category: nmr]] | [[Category: nmr]] | ||
| - | ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on | + | ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Mon Mar 31 04:11:53 2008'' |
Revision as of 01:11, 31 March 2008
| |||||||
| Ligands: | |||||||
| Gene: | BCL2L1, BCL2L, BCLX (Homo sapiens) | ||||||
| Resources: | FirstGlance, OCA, PDBsum, RCSB | ||||||
| Coordinates: | save as pdb, mmCIF, xml | ||||||
Solution structure of the anti-apoptotic protein Bcl-xL in complex with an acyl-sulfonamide-based ligand
Overview
Overexpression of the antiapototic proteins Bcl-2 and Bcl-xL provides a common mechanism through which cancer cells gain a survival advantage and become resistant to conventional chemotherapy. Inhibition of these prosurvival proteins is an attractive strategy for cancer therapy. We recently described the discovery of a selective Bcl-xL antagonist that potentiates the antitumor activity of chemotherapy and radiation. Here we describe the use of structure-guided design to exploit a deep hydrophobic binding pocket on the surface of these proteins to develop the first dual, subnanomolar inhibitors of Bcl-xL and Bcl-2. This study culminated in the identification of 2, which exhibited EC50 values of 8 nM and 30 nM in Bcl-2 and Bcl-xL dependent cells, respectively. Compound 2 demonstrated single agent efficacy against human follicular lymphoma cell lines that overexpress Bcl-2, and efficacy in a murine xenograft model of lymphoma when given both as a single agent and in combination with etoposide.
About this Structure
2O2M is a Single protein structure of sequence from Homo sapiens. Full crystallographic information is available from OCA.
Reference
Studies leading to potent, dual inhibitors of Bcl-2 and Bcl-xL., Bruncko M, Oost TK, Belli BA, Ding H, Joseph MK, Kunzer A, Martineau D, McClellan WJ, Mitten M, Ng SC, Nimmer PM, Oltersdorf T, Park CM, Petros AM, Shoemaker AR, Song X, Wang X, Wendt MD, Zhang H, Fesik SW, Rosenberg SH, Elmore SW, J Med Chem. 2007 Feb 22;50(4):641-62. Epub 2007 Jan 26. PMID:17256834
Page seeded by OCA on Mon Mar 31 04:11:53 2008
Categories: Homo sapiens | Single protein | Belli, B A. | Bruncko, M. | Ding, H. | Elmore, S W. | Fesik, S W. | Joseph, M K. | Kunzer, A. | Martineau, D. | McClellan, W J. | Mitten, M. | Ng, S C. | Nimmer, P M. | Oltersdorf, T. | Oost, T K. | Park, C M. | Petros, A M. | Rosenberg, S H. | Shoemaker, A R. | Song, X. | Wang, X. | Wendt, M D. | Zhang, H. | Apoptosis | Bcl | Complex | Nmr
